Journal of Diagnostics Concepts & Practice >
The diagnostic threshold for hypertension should not be lowered down to 130/80 mmhg: an academic perspective
Received date: 2023-06-24
Online published: 2023-12-18
Hypertension is a clinical diagnosis and is defined as the level of blood pressure (BP) at which the benefits of treatment unequivocally outweigh the risks of treatment, as documented by randomized controlled trials (RCTs). According to the current Chinese hypertension guidelines, the office BP threshold for diagnosing hypertension is systolic BP (SBP) ≥140 mmHg and/or diastolic BP (DBP) ≥90 mmHg. However, in the 2017 ACC/AHA hypertension guidelines the diagnostic threshold for hypertension was reduced to ≥130/80 mmHg with purpose of promoting more intensive BP treatment. Some Chinese experts suggest to adopt this new standard, but many more point out that such a change will impact severely on our healthcare system. This paper will explain why the BP threshold should not be lowered down to 130/80 mmHg from an academic perspective.During the past several decades a large number of RCTs have shown that, in hypertensive patients with drug treatment, lowering SBP/DBP to <140/90 mmHg is associated with significant reductions in major cardiovascular (CV) events and all-cause mortality. In 2003 American hypertension guidelines (JNC 7) recommended to treat patients with diabetes or chronic kidney disease (CKD) to BP goal of <130/80 mmHg. However, European experts found that recommendation was not supported by RCT evidence. The 2014 evidence-based American guidelines (JNC 8) drew the same conclusion and recommended a BP goal of <140/90 mmHg for hypertensive persons young than 60 years, including those with diabetes or CKD. The six recently published RCTs showed different results. Lowering SBP to <130/80 mmHg in patients with recent lacunar stroke did not result in a significant reduction of recurrent stroke in the SPS3 trial. Targeting a SBP of <120 mmHg did not reduce the rate of major CV events in the ACCORD study. Both the HOPE-3 trial and the CHINOM trial showed that in low-to-moderate risk patients with a BP in the high-normal range, antihypertensive drug treatment was not associated with a lower rate of major CV events than placebo. The SPRINT trial and the STEP study showed that intensive treatment with a SBP target of <120 mmHg or <130 mmHg resulted in a lower incidence of CV events. SPRINT trial was the major driver for the BP threshold changes introduced in the 2017 ACC/AHA guidelines. However, in the SPRINT trial a unique unattended BP measurement method was used that was different from methods used in previous studies. The SBP levels, when assessed by the unattended method, are usually much lower than when measured with conventional office BP measurement. Both the SPRINT trial and the STEP study are open-labelled and stopped early that typically provide exaggerated estimates of benefits. Both the studies required that patients in the standard treatment group stop taking antihypertensive drugs or have the doses reduced if their SBP dropped to below the lower limit of the target range. Reduction of therapy is not in line with clinical practice and would seem to bias the trial against the standard treatment. Thus, there still lacks high-quality evidence to convince us to reset the diagnostic threshold for hypertension to 130/80 mmHg, down from the current trigger of 140/90.
Key words： Hypertension; Diagnostic Threshold; Evidence-based medicine
SHI Zhongwei . The diagnostic threshold for hypertension should not be lowered down to 130/80 mmhg: an academic perspective[J]. Journal of Diagnostics Concepts & Practice, 2023 , 22(04) : 348 -361 . DOI: 10.16150/j.1671-2870.2023.04.004
| [1] | 王薇, 赵冬, 刘静, 等. 中国35-64岁人群血压水平与10年心血管病发病危险的前瞻性研究[J]. 中华内科杂志, 2004, 43(10):730-734. |
| [1] | WANG W, ZHAO D, LIU J, et al. A prospective study of relationship between blood pressure and 10-year cardiovascular risk in a Chinese cohort aged 35-64 years[J]. Zhonghua Nei Ke Za Zhi, 2004, 43(10):730-734. |
| [2] | 曾新颖, 刘世炜, 王黎君, 等. 2013年中国人群血压升高对死亡和期望寿命的影响[J]. 中华流行病学杂志, 2017, 38(8):1011-1016. |
| [2] | ZENG X Y, LIU S W, WANG L J, et al. Mortality and life expectancy that attributable to high blood pressure in Chinese people in 2013[J]. Zhonghua Liu Xing Bing Xue Za Zhi, 2017, 38(8):1011-1016. |
| [3] | CAO X, ZHAO Z, KANG Y, et al. The burden of cardiovascular disease attributable to high systolic blood pressure across China, 2005-18: a population-based study[J]. Lancet Public Health, 2022, 7(12):e1027-e1040. |
| [4] | 中国高血压防治指南修订委员会, 高血压联盟中国, 中华医学会心血管病学分会, 等. 中国高血压防治指南(2018年修订版)[J]. 中国心血管杂志, 2019, 24(1):24-56. |
| [4] | Writing Group of 2018 Chinese Guidelines for the Management of Hypertension, Chinese Hypertension League, Chinese Society of Cardiology, et al. 2018 Chinese guidelines for the management of hypertensionWriting Group of 2018[J]. Chin J Cardiovasc Med, 2019, 24(1):24-56. |
| [5] | 罗兰. 最新发布! 中国高血压诊断标准下调![EB/OL]. 光明网.(2022-11-14) [2023-4-8]. https://m.gmw.cn/baijia/2022-11/14/1303194218.html. |
| [5] | LUO L. Latest Release! The diagnostic criteria for hypertension in China have been lowered![EB/OL]. Guangming Net.(2022-11-14) [2023-4-8]. https://m.gmw.cn/baijia/2022-11/14/1303194218.html. |
| [6] | 钱童心. 中国高血压联盟主席: 高血压诊断标准下调不适合我国国情[N/OL]. 第一财经日报. 第A04版. (2022-11-16). https://www.yicai.com/news/101595160.html. |
| [6] | QIAN T X. Chairman of the Chinese Hypertension Alliance: Downregulation of hypertension diagnostic criteria is not suitable for China's national conditions[N/OL]. China Business News. A04. (2022-11-16). https://www.yicai.com/news/101595160.html. |
| [7] | CUNNINGHAM R L. MECHANISM AND CLINICAL ASPECTS OF CHRONIC ARTERIAL HYPERTENSION[J]. Cal State J Med, 1912, 10(7):303-305. |
| [8] | LüSCHER T F. What is a normal blood pressure?[J]. Eur Heart J, 2018, 39(24):2233-2240. |
| [9] | KOTCHEN T A. Historical trends and milestones in hypertension research: a model of the process of translational research[J]. Hypertension, 2011, 58(4):522-538. |
| [10] | MOSER M, ROCCELLA E J. The treatment of hypertension: a remarkable success story[J]. J Clin Hypertens (Greenwich), 2013, 15(2):88-91. |
| [11] | Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. A cooperative study[J]. JAMA, 1977, 237(3):255-261. |
| [12] | The Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The 1980 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure[J]. Arch Intern Med, 1980, 140(10):1280-1285. |
| [13] | The Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The 1984 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure[J]. Arch Intern Med, 1984, 144(5):1045-1057. |
| [14] | 1988 Joint National Committee. The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure[J]. Arch Intern Med, 1988, 148(5):1023-1038. |
| [15] | The Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure JNC V[J]. Arch Intern Med, 1993, 153(2):154-183. |
| [16] | The Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure[J]. Arch Intern Med, 1997, 157(21):2413-2446. |
| [17] | CHOBANIAN A V, BAKRIS G L, BLACK H R, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report[J]. JAMA, 2003, 289(19):2560-2572. |
| [18] | BüHLER F R, DOYLE A E, EPSTEIN F H, et al. Guidelines for the treatment of mild hypertension: memorandum from a WHO/ISH meeting[J]. Bull World Health Organ, 1983, 61(1):53-56. |
| [19] | ZANCHETTI A, CHALMERS J P, ARAKAWA K, et al. The 1993 guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting[J]. Blood Press, 1993, 2(2):86-100. |
| [20] | 刘力生, 龚兰生. 中国高血压防治指南(试行本)[J]. 中国医药导刊, 2000, 2(1):3-25. |
| [20] | LIU L S, GONG L S. Chinese Guidelines for the Prevention and Treatment of Hypertension (Trial Version)[J]. Chin J Med Guide, 2000, 2(1):3-25. |
| [21] | European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension[J]. J Hypertens, 2003, 21(6):1011-1053. |
| [22] | WILLIAMS B, MANCIA G, SPIERING W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension[J]. Eur Heart J, 2018, 39(33):3021-3104. |
| [23] | WILLIAMS B, POULTER N R, BROWN M J, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV[J]. J Hum Hypertens, 2004, 18(3):139-185. |
| [24] | National Institute for Health and Care Excellence (NICE). Hypertension in adults: diagnosis and management[EB/OL]. NICE guideline (NG 136).(2022-3-18) [2023-7-11]. https://www.nice.org.uk/guidance/ng136. |
| [25] | EVANS J G, ROSE G. Hypertension[J]. Br Med Bull, 1971, 27(1):37-42. |
| [26] | LEWINGTON S, CLARKE R, QIZILBASH N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies[J]. Lancet, 2002, 360(9349):1903-1913. |
| [27] | LIU L, ZHANG Y, LIU G, et al. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients[J]. J Hypertens, 2005, 23(12):2157-2172. |
| [28] | THOMOPOULOS C, PARATI G, ZANCHETTI A. Effects at different baseline and achieved blood pressure levels--overview and meta-analyses of randomized trials[J]. J Hypertens, 2014, 32(12):2296-2304. |
| [29] | BRUNSTR?M M, CARLBERG B. Association of Blood Pressure Lowering With Mortality and Cardiovascular Disease Across Blood Pressure Levels: A Systematic Review and Meta-analysis[J]. JAMA Intern Med, 2018, 178(1):28-36. |
| [30] | National Institute for Health and Care Excellence (NICE). Hypertension in adults: diagnosis and management[C/OL]. Evidence review for initiating treatment. NICE guideline (NG 136).(2019-8) [2023-7-11]. https://www.nice.org.uk/guidance/ng136/evidence/c-initiating-treatment-pdf-6896748208. |
| [31] | PATER C. The Blood Pressure "Uncertainty Range"-a pragmatic approach to overcome current diagnostic uncertainties (II)[J]. Curr Control Trials Cardiovasc Med, 2005, 6(1):5. |
| [32] | ZANCHETTI A, GRASSI G, MANCIA G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal[J]. J Hypertens, 2009, 27(5):923-934. |
| [33] | MANCIA G, LAURENT S, AGABITI-ROSEI E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document[J]. J Hypertens, 2009, 27(11):2121-2158. |
| [34] | B?HM M, SCHUMACHER H, TEO K K, et al. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials[J]. Lancet, 2017, 389(10085):2226-2237. |
| [35] | MANCIA G, KJELDSEN S E, ZAPPE D H, et al. Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial[J]. Eur Heart J, 2016, 37(12):955-964. |
| [36] | VERDECCHIA P, STAESSEN J A, ANGELI F, et al. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial[J]. Lancet, 2009, 374(9689):525-533. |
| [37] | CARLBERG B. Time to lower treatment BP targets for hypertension?[J]. Lancet, 2009, 374(9689):503-504. |
| [38] | CHOBANIAN A V, BAKRIS G L, BLACK H R, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure[J]. Hypertension, 2003, 42(6):1206-1252. |
| [39] | WRIGHT JT JR, BAKRIS G, GREENE T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial[J]. JAMA, 2002, 288(19):2421-2431. |
| [40] | MANCIA G, DE BACKER G, DOMINICZAK A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2007, 28(12):1462-1536. |
| [41] | 中国高血压防治指南修订委员会. 中国高血压防治指南2010[J]. 中华心血管病杂志, 39(7):579-616. |
| [41] | LIU L S, Writing Group of 2010 Chinese Guidelines for the Management of Hypertension. 2010 Chinese guidelines for the management of hypertension[J]. Zhonghua Xin Xue Guan Bing Za Zhi, 39(7):579-615. |
| [42] | SCHRIER R W, ESTACIO R O, ESLER A, et al. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes[J]. Kidney Int, 2002, 61(3):1086-1097. |
| [43] | WEBER M A, MATERSON B J. Hypertension guidelines: a major reappraisal critically examines the available evidence[J]. J Clin Hypertens(Greenwich), 2010, 12(4):229-236. |
| [44] | ARONOW W S. What should the optimal blood pressure goal be in patients with diabetes mellitus or chronic kidney disease?[J]. Arch Med Sci, 2012, 8(3):399-402. |
| [45] | 施仲伟. 血压目标将有回调,综合干预必须加强:从指南更新看高血压防治新动向[J]. 中华高血压杂志, 2012, 20(6):512-514. |
| [45] | SHI Z W. The blood pressure target will have a correction, and comprehensive intervention must be strengthened: new trends in hypertension prevention and control seen from the update of guidelines[J]. Chin J Hypertens, 2012, 20(6):512-514. |
| [46] | MANCIA G, FAGARD R, NARKIEWICZ K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2013, 34(28):2159-2219. |
| [47] | American Diabetes Association. Standards of medical care in diabetes—2013[J]. Diabetes Care, 2013, 36(Suppl 1):S11-S66. |
| [48] | WHELTON P K, CAREY R M, ARONOW W S, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines[J]. Hypertension, 2018, 71(6):e13-e115. |
| [49] | UMEMURA S, ARIMA H, ARIMA S, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)[J]. Hypertens Res, 2019, 42(9):1235-1481. |
| [50] | RABI D M, MCBRIEN K A, SAPIR-PICHHADZE R, et al. Hypertension Canada's 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children[J]. Can J Cardiol,2020, 36(5):596-624. |
| [51] | WILMOT K A, O'FLAHERTY M, CAPEWELL S, et al. Coronary Heart Disease Mortality Declines in the United States From 1979 Through 2011: Evidence for Stagnation in Young Adults, Especially Women[J]. Circulation,2015, 132(11):997-1002. |
| [52] | MA J, WARD E M, SIEGEL R L, et al. Temporal Trends in Mortality in the United States, 1969-2013[J]. JAMA, 2015, 314(16):1731-1739. |
| [53] | SIDNEY S, QUESENBERRY CP JR, JAFFE M G, et al. Recent Trends in Cardiovascular Mortality in the United States and Public Health Goals[J]. JAMA Cardiol, 2016, 1(5):594-599. |
| [54] | MATERSON B J. JNC 8 at last! No Holy Grail in hand, but useful recommendations[J]. J Clin Hypertens (Greenwich), 2014, 16(4):249-250. |
| [55] | FINKS S, REPLEY T L. Sorting it out: what JNC 8 is and what it is not[J]. J Manag Care Spec Pharm, 2015, 21(2):110-112. |
| [56] | MATERSON B J. JNC 8 transmogrified[J]. J Clin Hypertens (Greenwich), 2013, 15(10):704. |
| [57] | BAUCHNER H, FONTANAROSA P B, GOLUB R M. Updated guidelines for management of high blood pressure: recommendations, review, and responsibility[J]. JAMA, 2014, 311(5):477-478. |
| [58] | GIBBONS G H, SHURIN S B, MENSAH G A, et al. Refocusing the agenda on cardiovascular guidelines: an announcement from the National Heart, Lung, and Blood Institute[J]. Circulation, 2013, 128(15):1713-1715. |
| [59] | GIBBONS G H, HAROLD J G, JESSUP M, et al. The next steps in developing clinical practice guidelines for prevention[J]. Circulation, 2013, 128(15):1716-1717. |
| [60] | JAMES P A, OPARIL S, CARTER B L, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)[J]. JAMA, 2014, 311(5):507-520. |
| [61] | BENAVENTE O R, WHITE C L, PEARCE L, et al. The Secondary Prevention of Small Subcortical Strokes (SPS3) study[J]. Int J Stroke, 2011, 6(2):164-175. |
| [62] | SPS 3 Investigators; BENAVENTE O R, HART R G, MCCLURE L A, et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke[J]. N Engl J Med, 2012, 367(9):817-825. |
| [63] | SPS 3 Study Group; BENAVENTE O R, COFFEY C S, CONWIT R, et al. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial[J]. Lancet, 2013, 382(9891):507-515. |
| [64] | ACCORD Study Group; BUSE J B, BIGGER J T, BYINGTON R P, et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods[J]. Am J Cardiol, 2007, 99(12 A):21i-33i. |
| [65] | CUSHMAN W C, GRIMM RH JR, CUTLER J A, et al. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial[J]. Am J Cardiol, 2007, 99(12A):44i-55i. |
| [66] | ACCORD Study Group; CUSHMAN W C, EVANS G W, BYINGTON R P, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus[J]. N Engl J Med, 2010, 362(17):1575-1585. |
| [67] | Working Group Report: Expert Panel on a Hypertension Treatment Trial Initiative Meeting Summary[R/OL]. (2007-1-16)[2023-7-8]. https://www.nhlbi.nih.gov/sites/default/files/media/docs/hypertsnsion-full.pdf. |
| [68] | AMBROSIUS W T, SINK K M, FOY C G, et al. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT)[J]. Clin Trials, 2014, 11(5):532-546. |
| [69] | VERDECCHIA P, ANGELI F, REBOLDI G, et al. The SPRINT trial[J]. J Am Soc Hypertens, 2015, 9(10):750-753. |
| [70] | SPRINT Research Group; WRIGHT JT JR, WILLIAMSON J D, WHELTON P K, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control[J]. N Engl J Med, 2015, 373(22):2103-2116. |
| [71] | GREENLAND P, PETERSON E. The New 2017 ACC/AHA Guidelines “Up the Pressure” on Diagnosis and Treatment of Hypertension[J]. JAMA, 2017, 318(21):2083-2084. |
| [72] | Kidney Disease: Improving Global Outcomes KDIGO Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease[J]. Kidney Int, 2021, 99(3S):S1-S87. |
| [73] | MYERS M G, GODWIN M, DAWES M, et al. Measurement of blood pressure in the office: recognizing the problem and proposing the solution[J]. Hypertension, 2010, 55(2):195-200. |
| [74] | KJELDSEN S E, LUND-JOHANSEN P, NILSSON P M, et al. Unattended Blood Pressure Measurements in the Systolic Blood Pressure Intervention Trial: Implications for Entry and Achieved Blood Pressure Values Compared With Other Trials[J]. Hypertension, 2016, 67(5):808-812. |
| [75] | BUNDY J D, LI C, STUCHLIK P, et al. Systolic Blood Pressure Reduction and Risk of Cardiovascular Disease and Mortality: A Systematic Review and Network Meta-analysis[J]. JAMA Cardiol, 2017, 2(7):775-781. |
| [76] | BAKRIS G L. The Implications of Blood Pressure Measurement Methods on Treatment Targets for Blood Pressure[J]. Circulation, 2016, 134(13):904-905. |
| [77] | BAKRIS G L. Response by Bakris to Letter Regarding Article, "The Implications of Blood Pressure Measurement Methods on Treatment Targets for Blood Pressure"[J]. Circulation, 2017, 135(7):e47. |
| [78] | WILLIAMSON J D, SUPIANO M A, APPLEGATE W B, et al. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial[J]. JAMA, 2016, 315(24):2673-2682. |
| [79] | JOHNSON K C, WHELTON P K, CUSHMAN W C, et al. Blood Pressure Measurement in SPRINT (Systolic Blood Pressure Intervention Trial)[J]. Hypertension, 2018, 71(5):848-857. |
| [80] | FILIPOVSKY J, SEIDLEROVá J, KRATOCHVíL Z, et al. Automated compared to manual office blood pressure and to home blood pressure in hypertensive patients[J]. Blood Press, 2016, 25(4):228-234. |
| [81] | AGARWAL R. Implications of Blood Pressure Measurement Technique for Implementation of Systolic Blood Pressure Intervention Trial (SPRINT)[J]. J Am Heart Assoc, 2017, 6(2):e004536. |
| [82] | BAUER F, SEIBERT F S, ROHN B, et al. Attended Versus Unattended Blood Pressure Measurement in a Real Life Setting[J]. Hypertension, 2018, 71(2):243-249. |
| [83] | PAINI A, BERTACCHINI F, STASSALDI D, et al. Unattended versus attended blood pressure measurement: Mean values and determinants of the difference[J]. Int J Cardiol, 2019, 274:305-310. |
| [84] | CHENG R Z, BHALLA V, CHANG T I, et al. Comparison of routine and automated office blood pressure measurement[J]. Blood Press Monit, 2019, 24(4):174-178. |
| [85] | YUSUF S, LONN E. The SPRINT and the HOPE-3 Trial in the Context of Other Blood Pressure-Lowering Trials[J]. JAMA Cardiol, 2016, 1(8):857-858. |
| [86] | FILIPPONE E J, FOY A J. Blood pressure management in the wake of SPRINT[J]. Clev Clin J Med, 2016, 83(3):196-198. |
| [87] | KJELDSEN S E, NARKIEWICZ K, HEDNER T, et al. The SPRINT study: Outcome may be driven by difference in diuretic treatment demasking heart failure and study design may support systolic blood pressure target below 140?mmHg rather than below 120?mmHg[J]. Blood Press, 2016, 25(2):63-66. 88. |
| [88] | LONN E M, YUSUF S. Should Patients With Cardiovascular Risk Factors Receive Intensive Treatment of Hypertension to <120/80 mm?Hg Target? An Antagonist View From the HOPE-3 Trial (Heart Outcomes Evaluation-3)[J]. Circulation, 2016, 134(18):1311-1313. |
| [89] | SHAPIRO B P, AMBROSIUS W T, BLACKSHEAR J L, et al. Impact of Intensive Versus Standard Blood Pressure Management by Tertiles of Blood Pressure in SPRINT (Systolic Blood Pressure Intervention Trial)[J]. Hypertension, 2018, 71:1064-1074. |
| [90] | LONN E, BOSCH J, POGUE J, et al. Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics[J]. Can J Cardiol, 2016, 36(3):311-318. |
| [91] | LONN E M, BOSCH J, LóPEZ-JARAMILLO P, et al. Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease[J]. N Engl J Med, 2016, 374(21):2009-2020. |
| [92] | PAIS P, JUNG H, DANS A, et al. Impact of blood pressure lowering, cholesterol lowering and their combination in Asians and non-Asians in those without cardiovascular disease: an analysis of the HOPE 3 study[J]. Eur J Prev Cardiol, 2019, 26(7):681-697. |
| [93] | ZHANG S, WU S, REN J, et al. Strategy of blood pressure intervention in the elderly hypertensive patients (STEP): Rational, design, and baseline characteristics for the main trial[J]. Contemp Clin Trials, 2020, 89:105913. |
| [94] | 张宇清, 苗欢欢, 杨世杰, 等. 谋定后动——新近高血压重要研究中的启示[J]. 中国介入心脏病学杂志, 2022, 30(7):518-521. |
| [94] | ZHANG Y Q, MIAO H H, YANG S J, et al. Planning after Action: Enlightenment from Recent Important Research on Hypertension[J]. Chin J Interv Cardiol, 2022, 30(7):518-521. |
| [95] | ZHANG W, ZHANG S, DENG Y, et al. Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension[J]. N Engl J Med, 2021, 385(14):1268-1279. |
| [96] | NELSON M R. Moving the Goalposts for Blood Pressure-Time to Act[J]. N Engl J Med, 2021, 385(14):1328-1329. |
| [97] | BENETOS A, PERSU A, KREUTZ R. Hypertension in older patients: a STEP forward?[Formula: see text][J]. Blood Press, 2022, 31(1):118-120. |
| [98] | UNGER T, BORGHI C, CHARCHAR F, et al. 2020 International Society of Hypertension global hypertension practice guidelines[J]. J Hypertens, 2020, 38(6):982-1004. |
| [99] | AL-MAKKI A, DIPETTE D, WHELTON P K, et al. Hypertension Pharmacological Treatment in Adults: A World Health Organization Guideline Executive Summary[J]. Hypertension, 2022, 79(1):293-301. |
| [100] | MANCIA G, KREUTZ R, BRUNSTR?M M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)[J]. J Hypertens, 2023, 41(12):1874-2071. |
| [101] | CHEN X, BARYWANI S B, HANSSON P O, et al. High-normal blood pressure conferred higher risk of cardiovascular disease in a random population sample of 50-year-old men: A 21-year follow-up[J]. Medicine (Baltimore), 2020, 99(17):e19895. |
| [102] | MUSCAT D M, MORRIS G M, BELL K, et al. Benefits and Harms of Hypertension and High-Normal Labels: A Randomized Experiment[J]. Circ Cardiovasc Qual Outcomes, 2021, 14(4):e007160. |
| [103] | HAMER M, BATTY G D, STAMATAKIS E, et al. Hypertension awareness and psychological distress[J]. Hypertension, 2010, 56(3):547-550. |
| [104] | RANTANEN A T, KORKEILA J J A, L?YTTYNIEMI E S, et al. Awareness of hypertension and depressive symptoms: a cross-sectional study in a primary care population[J]. Scand J Prim Health Care, 2018, 36(3):323-328. |
| [105] | 王继光. 必须高度重视降压药物治疗的安全性[J]. 中华心血管病杂志, 2022, 50(7):625-626. |
| [105] | WANG J G. [Taking the safety of antihypertensive drug treatment seriously][J]. Zhonghua Xin Xue Guan Bing Za Zhi, 2022, 50(7):625-626. |
| [106] | 潘锋. CHINOM研究填补国内外心血管疾病同类研究空白——正常高值血压人群如无其他严重疾病无需服用降压药[J]. 中国医药科学, 2022, 12(11):1-4. |
| [106] | PAN F. CHINOM research fills the gap in similar research on cardiovascular diseases both domestically and internationally - people with normal high blood pressure do not need to take antihypertensive drugs if there are no other serious diseases[J]. China Med Pharm, 2022, 12(11):1-4. |
| [107] | 医师报循环频道. 该怎么看待CHINOM研究?张新华教授等独家解读[EB/OL]. 医师报循环频道.(2022-5-17) [2023-7-17]. https://mp.pdnews.cn/Pc/ArtInfoApi/article?id=28689628. |
| [108] | KREUTZ R, BRUNSTR?M M, THOMOPOULOS C, et al. Do recent meta-analyses truly prove that treatment with blood pressure-lowering drugs is beneficial at any blood pressure value, no matter how low? A critical review[J]. J Hypertens, 2022, 40(5):839-846. |
| [109] | BASSLER D, MONTORI V M, BRIEL M, et al. Early stopping of randomized clinical trials for overt efficacy is problematic[J]. J Clin Epidemiol, 2008, 61(3):241-246. |
| [110] | NOLDE J M, BEANEY T, CARNAGARIN R, et al. Global Impact of Different Blood Pressure Thresholds in 4 021 690 Participants of the May Measurement Month Initiative[J]. Hypertension, 2022, 79(7):1497-1505. |
/
| 〈 |
|
〉 |
